tiprankstipranks
Trending News
More News >
Kyntra Bio (KYNB)
NASDAQ:KYNB

Kyntra Bio (KYNB) Stock Statistics & Valuation Metrics

Compare
1,064 Followers

Total Valuation

Kyntra Bio has a market cap or net worth of $28.32M. The enterprise value is -$68.62M.
Market Cap$28.32M
Enterprise Value-$68.62M

Share Statistics

Kyntra Bio has 4,045,445 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding4,045,445
Owned by Insiders10.61%
Owned by Institutions0.76%

Financial Efficiency

Kyntra Bio’s return on equity (ROE) is 40.99 and return on invested capital (ROIC) is -50.72%.
Return on Equity (ROE)40.99
Return on Assets (ROA)1.53
Return on Invested Capital (ROIC)-50.72%
Return on Capital Employed (ROCE)-0.51
Revenue Per Employee28.62K
Profits Per Employee815.34K
Employee Count225
Asset Turnover0.05
Inventory Turnover0.00

Valuation Ratios

The current PE Ratio of Kyntra Bio is <0.1. Kyntra Bio’s PEG ratio is -0.00002.
PE Ratio<0.1
PS Ratio5.51
PB Ratio7.93
Price to Fair Value7.93
Price to FCF-7.38
Price to Operating Cash Flow-1.67
PEG Ratio-0.00002

Income Statement

In the last 12 months, Kyntra Bio had revenue of 6.44M and earned 183.45M in profits. Earnings per share was 45.37.
Revenue6.44M
Gross Profit0.00
Operating Income-45.90M
Pretax Income-58.29M
Net Income183.45M
EBITDA-45.90M
Earnings Per Share (EPS)45.37

Cash Flow

In the last 12 months, operating cash flow was -4.77M and capital expenditures -38.00K, giving a free cash flow of -4.81M billion.
Operating Cash Flow-4.77M
Free Cash Flow-4.81M
Free Cash Flow per Share-1.19

Dividends & Yields

Kyntra Bio pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share
Dividend Yield
Payout RatioN/A
Free Cash Flow Yield
Earnings Yield

Stock Price Statistics

Beta1.09
52-Week Price Change-37.08%
50-Day Moving Average8.03
200-Day Moving Average8.87
Relative Strength Index (RSI)41.89
Average Volume (3m)30.76K

Important Dates

Kyntra Bio upcoming earnings date is May 11, 2026, After Close (Confirmed).
Last Earnings DateMar 16, 2026
Next Earnings DateMay 11, 2026
Ex-Dividend Date

Financial Position

Kyntra Bio as a current ratio of 3.39, with Debt / Equity ratio of -123.56%
Current Ratio3.39
Quick Ratio3.26
Debt to Market Cap0.00
Net Debt to EBITDA1.04
Interest Coverage Ratio5.24

Taxes

In the past 12 months, Kyntra Bio has paid -90.00K in taxes.
Income Tax-90.00K
Effective Tax Rate<0.01

Enterprise Valuation

Kyntra Bio EV to EBITDA ratio is 0.27, with an EV/FCF ratio of 2.57.
EV to Sales-1.92
EV to EBITDA0.27
EV to Free Cash Flow2.57
EV to Operating Cash Flow2.59

Balance Sheet

Kyntra Bio has $88.98M in cash and marketable securities with $0.00 in debt, giving a net cash position of $88.98M billion.
Cash & Marketable Securities$88.98M
Total Debt$0.00
Net Cash$88.98M
Net Cash Per Share$21.99
Tangible Book Value Per Share$1.11

Margins

Gross margin is 82.74%, with operating margin of -712.66%, and net profit margin of 2848.63%.
Gross Margin82.74%
Operating Margin-712.66%
Pretax Margin-905.19%
Net Profit Margin2848.63%
EBITDA Margin-712.66%
EBIT Margin0.00%

Analyst Forecast

The average price target for Kyntra Bio is $25.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$25.00
Price Target Upside257.14% Upside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast-95.39%
EPS Growth Forecast

Scores

Smart ScoreN/A
AI Score